View Older Stories View More Recent Stories

Mar 20, 2017 05:41AM Amgen (AMGN) Repatha Did Not Adversely Affect Cognitive Function in Phase 3 Trial
Mar 19, 2017 02:00PM Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients
Mar 18, 2017 08:00AM Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study
Mar 17, 2017 09:01AM Amgen (AMGN) Says Outcomes Study Shows Repatha Decreases LDL-C to Unprecedented Low Levels, Reduces Risk of Cardiovascular Events
Mar 17, 2017 09:00AM Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues
Mar 16, 2017 04:00PM Amgen To Present At The Oppenheimer Global Health Care Conference
Mar 14, 2017 04:17PM Amgen (AMGN) Says Repatha Four-Year Open-Label Follow-Up Study Published in 'JAMA Cardiology'
Mar 14, 2017 04:15PM Repatha® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology'
Mar 14, 2017 04:00PM Amgen To Webcast Investor Meeting At Upcoming American College Of Cardiology Scientific Sessions
Mar 13, 2017 09:08AM Amgen (AMGN) Announces Positive Top-Line Phase 3 Study Results for Repatha® (Evolocumab)
Mar 13, 2017 09:00AM Repatha® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study
Mar 8, 2017 06:12AM 'It's like kumbaya': Trump's genial private meetings with CEOs jar with public attacks
Mar 7, 2017 04:00PM Amgen Announces 2017 Second Quarter Dividend
Mar 6, 2017 04:00PM Amgen Highlights Landmark Repatha® (Evolocumab) Cardiovascular Outcomes Study Amongst Data To Be Presented At ACC.17
Mar 3, 2017 04:02PM Amgen (AMGN) Presents Overall Survival Data From KYPROLIS Phase 3 ENDEAVOR Trial
Mar 3, 2017 04:01PM Amgen (AMGN) Presents New Data From Phase 3 XGEVA Study
Mar 3, 2017 04:00PM Amgen Presents New Data From Phase 3 XGEVA® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop
Mar 3, 2017 04:00PM Amgen Presents Overall Survival Data From KYPROLIS® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop
Mar 2, 2017 04:00PM Amgen To Present At The Cowen And Company 37th Annual Health Care Conference
Mar 1, 2017 05:13PM Amgen (AMGN) Says NEJM Published Results of Phase 3 TOWER Study Evaluating Efficacy of BLINCYTO; Results Show Significantly Improved Overall Survival in B-Cell ALL
Mar 1, 2017 05:09PM BLINCYTO® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
Mar 1, 2017 04:00PM Amgen To Present New KYPROLIS® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop
Feb 28, 2017 09:02AM Amgen (AMGN) Says Phase 3 Head-to-Head Trial Showed KYPROLIS Significantly Improved Overall Survival Compared to Velcade in Refractory Multiple Myeloma Patients
Feb 28, 2017 09:00AM Phase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients
Feb 21, 2017 04:01PM Amgen's (AMGN) Repatha Receives EC Approval For New 420 mg Single-Dose Delivery Option
Feb 21, 2017 04:00PM Repatha® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Feb 14, 2017 09:01AM Amgen (AMGN) Submits sBLA for BLINCYTO
Feb 14, 2017 09:00AM Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Feb 9, 2017 09:24AM Pre-Open Movers 02/09: (OSUR) (ACOR) (PAYC) Higher; (TWTR) (OII) (QLYS) Lower (more...)
Feb 8, 2017 05:32PM Regeneron (REGN) and Sanofi (SNY) Confirm Stay of Permanent Injunction for Praluent (AMGN)
Feb 7, 2017 06:14PM Amgen (AMGN) Granted FDA Approval for Parsabiv
Feb 7, 2017 06:13PM FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
Feb 3, 2017 04:04PM Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors
Feb 2, 2017 04:20PM Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
Feb 2, 2017 04:01PM Amgen's (AMGN) Repatha Trail Met Primary Endpoint in Reducing Risk of Cardiovascular Events
Feb 2, 2017 04:00PM Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Jan 30, 2017 04:00PM Amgen Announces Webcast of 2016 Fourth Quarter and Full Year Financial Results
Jan 27, 2017 07:43AM Amgen (AMGN) Announces Positive CHMP Opinion For ABP 501 For to Treat Certain Inflammatory Diseases
Jan 27, 2017 07:38AM Amgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
Jan 10, 2017 04:20PM Amgen (AMGN) Announces Study Results on Parsabiv in sHPT Published in JAMA
Jan 10, 2017 04:12PM Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv™ (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparath
Jan 9, 2017 06:21AM Amgen (AMGN) Enters New Six-Year Sourcing and Supply Agreement with DaVita (DVA)
Jan 9, 2017 06:00AM Amgen And DaVita Enter Into New Sourcing And Supply Agreement
Jan 9, 2017 04:02AM Amgen (AMGN), Immatics Biotechnologics To Collaborate On Novel Bispecific Cancer Immunotherapies Development
Jan 9, 2017 04:00AM Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies
Jan 6, 2017 01:19AM Amgen (AMGN) Request For Permanent Injunction For Repatha Patent Infringement By Sanofi & Regeneron Granted By US Court
Jan 5, 2017 09:34PM Court Grants Permanent Injunction For Infringement Of Amgen's Repatha Patents
Jan 4, 2017 04:00PM Amgen To Present At The 35th Annual J.P. Morgan Healthcare Conference
Dec 20, 2016 04:20PM Amgen Announces 15 Percent Increase In 2017 First Quarter Dividend
Dec 19, 2016 07:00PM Amgen And UCB Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan
View More Recent Stories View Older Stories